...
ZLABLARGE

Zai Lab Limited

HealthcareBiotechnology
$19.22
$0.00(-2.39%)
52W$15.96
$44.34
FinancialsValuationvs UTHR
Updated Mar 2, 12:00 AM
RSI58
RS Rating22/99
Beta0.99
Volatility63%
F-Score3/9
Mkt Cap$21.3B
WEAKENING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

WEAKENING

Zai Lab Limited is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 22), showing significant lag compared to the market leaders. Earnings growth of 44% provides fundamental context to the price action. Investors should exercise caution due to high volatility (63% annualized), which requires wider risk management.

Relative Strength
22
out of 99
Lagging
Trend Score
1/4
Minervini Criteria
WEAKENING
Risk (Beta)
0.99
vs S&P 500
MARKET
52W Position
11%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

WEAKENING1/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$18.36
50 SMA > 100 SMA$21.03
100 SMA > 150 SMA$25.36
150 SMA > 200 SMA$27.78

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$18.72+2.67%ABOVE
50 SMA$18.36+4.71%ABOVE
100 SMA$21.03-8.62%BELOW
150 SMA$25.36-24.21%BELOW
200 SMA$27.78-30.82%BELOW

Price Performance

1D-2.4%
1W-2.5%
1M+11.7%
3M-5.8%
6M-40.3%
YTD+10.9%
1Y-44.5%
3Y-19.7%
52-Week Trading Range11% from low
$19.22
52W Low$15.96
52W High$44.34

Technical Indicators

RSI (14)NEUTRAL
57.7
305070
VCP ScoreCOOL
7/10
Base depth: 22.3%

Risk Profile

Beta
0.99
52W Vol
63%
ATR
$0.86
Max DD (1Y)
-62%

Volume Analysis

Today
19
50D Avg
622.1K
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25+92%
$-0.45
Q2'25+95%
$-0.37
Q3'25+92%
$-0.33
Q4'25+44%
$-0.45
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+56.54%
3 Years:+28.86%
TTM:+15.33%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+91.49%

Stock Price CAGR

10 Years:-3.67%
5 Years:-34.71%
3 Years:-19.72%
1 Year:-44.52%

Return on Equity

10Y Avg:-44.7%
5Y Avg:-36.4%
3Y Avg:-30.1%
Last Year:-24.5%

Key Metrics

Market Cap$21.3B
Gross Margin58.6%
Net Margin-38.1%
Piotroski F-Score3/9

More ZLAB Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ZLAB vs UTHRUTHRAMRNALKSADMA

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 22 meansZLAB outperformed 22% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.99 means 1% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 7/10 with COOL status.

Frequently Asked Questions

Is ZLAB in an uptrend right now?

ZLAB has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.

Is ZLAB overbought or oversold?

ZLAB's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.

Is ZLAB outperforming the market?

ZLAB has a Relative Strength (RS) Rating of 22 out of 99. ZLAB is currently lagging the broader market.

Where is ZLAB in its 52-week range?

ZLAB is trading at $19.22, which is 43% of its 52-week high ($44.34) and 11% above its 52-week low ($15.96).

How volatile is ZLAB?

ZLAB has a Beta of 0.99 and 52-week volatility of 63%. It's less volatile than the S&P 500 - generally more stable.